Contagion Editorial Team

From chikungunya setbacks to COVID-19 booster guidance and childhood vaccine safety initiatives, here are the top regulatory and research developments this summer.

The American College of Cardiology is providing recommendations on the influenza, COVID-19, RSV vaccinations and others.

The designation is for the company’s TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.

Full committee removal raises concerns over vaccine policy stability and scientific independence.

This week, FDA approved Moderna’s improved COVID-19 vaccine mRNA, MAD-ID findings showed omadacycline’s 86% success rate in treating infections in immunocompromised patients, consistent safety in preventing recurrent CDI in patients with comorbidities, and more.

Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.

A published study reveals how an extra gene allows a specific mycetoma-causing fungus to neutralize itraconazole when treating the neglected tropical disease.

Innoviva launches ceftobiprole in the US, shifts in FDA COVID-19 vaccine policy, a surge in fungal infections, and more.

A Centers for Disease Control and Prevention (CDC) publication reports on REPEXH01, a strain of Shiga toxin–producing Escherichia coli (STEC) O157:H7, which has been responsible for at least 9 outbreaks in the US since 2017.

The company detailed its preliminary 24-week post–end-of-treatment data for its tobevibart and elebsiran combination, which is being studied for chronic hepatitis B.

A study of an H5N1 strain from a Michigan dairy worker showed airborne transmission in ferrets, bulevirtide achieved sustained virologic response in chronic hepatitis D patients, and more.

Rising tick-borne illnesses due to warmer winters, strong hepatitis E vaccine efficacy during an outbreak, emerging fungal threats and resistance, and more.

The University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) announced its initiative that will look to ensure reliable vaccine data and information is available to the public and medical community.

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Development of a monoclonal antibody targeting mucormycosis, WHO’s call for improved fungal diagnostics and therapies, Bayesian dosing to optimize antimicrobial therapy, and more.

This week, the FDA approved two new drugs, gepotidacin for treating uUTIs in females aged 12 and older, and Tesamorelin F8 for managing excess abdominal fat in adults with HIV-associated lipodystrophy.

The department is set to lay off 10,000 full-time employees, and with combined efforts, expects the reduction to be a total downsizing of 20,000 employees.

Emblaveo for multidrug-resistant infections, advancing RNA therapies and new vaccine options, Vaxart's oral norovirus vaccine, and synthetic gel for ABSSSI, and more.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

This week, five all-oral TB regimens showed efficacy, fungal biofilm diseases remain challenging, over 2 million pastries were recalled due to contamination, and more.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

The new version of its molecular test targets the causes of gastroenteritis.

This week, a study on children with invasive candidiasis showed that switching treatment was just as effective, AI is being explored as a tool to combat AMR, and more.

This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.

Cabotegravir (Vocabria) + rilpivirine (Rekambys) is the first and only complete long-acting injectable regimen for the treatment of HIV.

The company said its oral therapy, S-337395, achieved a 88.94% reduction in viral load.

The fully cooked frozen product was not recalled because the product can no longer be purchased. This does apply to consumers who have the product at home.